WHO Biosimilars Prequalification Pilot

[membership level=”0,4″][The content continues for paid members only.] Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership] WHO announced a pilot project for prequalifying biosimilar medicines and invites manufacturers to submit applications for two products in the WHO Essential Medicines List: rituximab, and trastuzumab. If WHO finds the biosimilars submitted for prequalification are comparable to originator products, the medicines will be listed by WHO and become eligible for procurement by United Nations agencies. WHO will also review its 2009 Guidelines on the evaluation of similar biotherapeutic products.
[/membership]